MGTX has great potential with its breakthrough technologies in Gene Therapies, especially for treatment of Inherited Retina Diseases (IRD). Singapore National Eye Centre (SNEC) has shown great interest in Gene therapies with its relatively recent set up of department of IRD within SNEC itself. The latest UK regulatory approval of one of MGTX solutions is yet another indication of MGTX great potential for upside in its price. No wonder that current postmarket price hits $6.75 #MGTX
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- Boon118·07-01TOPThe Inherited Retinal Diseases that MGTX is currently working on is X-linked Retinitis Pigmentosa (XLRP) and MGTX has completed Phase 3 studies. There's no other known cure for RP except this optimistic XLRP Gene therapy by MGTXLikeReport
- Boon118·07-01Amendment: I meant the latest UK regulatory approval for transaction with HologenLikeReport